Nearly 26 millions PLN for rare diseases studies

14.07.2021

Agencja Badań Medycznych (Medical Research Agency) has published results of contest concerning non-commercial research in the field of rare diseases on 9th of July 2021. From 12 financed projects 3 will be realised or co-realised by the Medical University of Gdańsk. Contest’s budget was 100 mln PLN high, of which 25 799 906,16 PLN were allocated to projects that will be carried out at our University. In each of them the Head Researcher is a specialist from our University.

From left: Lidia Woźniak-Mielczarek Ph.D., Prof. Piotr Czauderna, Prof. Maria Alicja Dębska-Ślizień

Lidia Woźniak-Mielczarek Ph.D. from the Department of Paediatric Cardiology and Congenital Heart Defects will be the Head Researcher and National Coordinator of project Ocena skuteczności walsartanu w zwalnianiu poszerzania się aorty u dzieci i młodych dorosłych z uwarunkowanymi genetycznie chorobami aorty piersiowej typu zespołu Marfana – wieloośrodkowe badanie randomizowane kontrolowane placebo z podwójnie ślepą próbą (Valsartan in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomized, multicentre, double-blind, placebo-controlled trial), realised in the consortium with the Polish Mother’s Memorial Hospital Research Institute and the Polish Marfan Association, which leader is the MUG. 9 682 866,20 PLN have been allocated for this project.

Prof. Piotr Czauderna, Head of the Department of Surgery and Urology for Children and Adolescents will be the Head Researcher and National Coordinator of project Badanie kliniczne obejmujące dzieci i młodzież z pierwotnym złośliwym nowotworem wątroby – wątrobiakiem zarodkowym (Hepatoblastoma) i rakiem wątrobowokomórkowym (Hepatocarcinoma) – POLPHITT (Clinical study on children and youth with hepatoblastoma and hepatocarcinoma) – POLPHITT which will be conducted by our University on its own. 6 117 040,00 PLN have been allocated for this project.

Prof. Maria Alicja Dębska-Ślizień, Head of the Department of Nephrology, Transplantology and Internal Diseases within the consortium will manage tasks assigned to the MUG in project VASCULITIS – Personalizowane leczenie immunosupresyjne z użyciem rituximabu w leczeniu układowych zapaleń naczyń z obecnością przeciwciał ANCA – randomizowane, wieloośrodkowe badanie kliniczne (VASCULITIS – Personalised immunosuppresive treatment with use of ritumixab in the treatment of vasculitis with ANCA antibodies presence – randomised, multi-central clinical study). Consortium’s leader is the Military Institute of Medicine. Moreover, it’s also composed of the Medical University of Łódź and Association of People Sick with Vasculitis Vasculitis. 9 999 999,98 PLN have been allocated for this project.